Products for Research Use Only

ELQ-300

CAT: 0804-HY-13836-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13836-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ELQ-300 is a potent and orally bioavailable antimalarial agent, acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1) . ELQ-300 inhibits growth of P. falciparum Dd2, Tm90-C2B, and D1 with IC50 values of 6.6, 4.6 and 160 nM, respectively. ELQ-300 can be used for the research of antimalarial[1][2].
CAS Number
1354745-52-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Parasite
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/elq-300.html
Purity
98.0
Solubility
DMSO : 15.62 mg/mL (ultrasonic)
Smiles
O=C1C(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=C(C)NC4=C1C=C(Cl)C(OC)=C4
Molecular Formula
C24H17ClF3NO4
Molecular Weight
475.84
Precautions
H302, H315, H319, H335
References & Citations
[1]Stickles AM, et al. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum. Antimicrob Agents Chemother. 2015 Apr;59 (4) :1977-82.|[2]Stickles AM, et al. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother. 2016 Jul 22;60 (8) :4853-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Plasmodium